EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial

Cristina Marcelo-Calvo iD, Andrés Esteban-Cantos, Francisco Jurado, Rocío Montejano iD, Lucía Gutiérrez-García, Alejandro de Gea-Grela, Patricia Martínez-Martín, Alejandro Díez-Vidal iD, Rosa de Miguel Buckley, Carlos M Oñoro-López, Juan C González, Luz Martín-Carbonero und 5 weitere

Open Forum Infectious Diseases · 01.08.2026 · 13 (8)

DOI: 10.1093/ofid/ofag489 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 06.08.2026. Verfasst von Cristina Marcelo-Calvo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, HIV Unit, La Paz University Hospital, Madrid, Spain. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union, Fondo Social Europeo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Weight gain is a major complication of contemporary antiretroviral treatment (ART). We evaluated the effects of metformin on weight trajectories and metabolic outcomes in non-diabetic, non-obese, older persons with HIV-1 (PWH).

Methods

In this double-blind, randomized, placebo-controlled pilot trial (METFORAGING), PWH 50 years or older, virologically suppressed, without diabetes or insulin resistance, were randomly assigned (1:1) to metformin 850 mg or placebo twice daily for 96 weeks at La Paz University Hospital (Madrid, Spain). This prespecified secondary analysis evaluated changes in body weight, body mass index (BMI), glycemic indices, lipid parameters, and serum growth differentiation factor-15 (GDF-15) in the per-protocol population.

Results

Forty participants were randomly assigned (metformin n = 19; placebo n = 21); 35 completed treatment through week 96 (per-protocol population). At week 96, mean weight change was −1.5 kg (95% CI −2.9 to −0.03) with metformin and +1.3 kg (−0.7 to 3.3) with placebo (between-group difference −2.8 kg [95% CI −5.2 to −0.4]; P = .025). After discontinuation, weight in the metformin group returned toward baseline (between-group difference from week 96 to 144: 2.2 kg [95% CI 0.05 to 4.5]; P = .045). At week 96, changes in body weight correlated inversely with changes in serum GDF-15 in the metformin group (r = −0.67; P = .003). No serious adverse events were attributed to metformin.

Conclusions

Metformin attenuated weight gain in nondiabetic, nonobese PWH receiving contemporary ART, but the effect was not sustained after discontinuation. These findings support larger trials to confirm efficacy and define optimal treatment duration. Trial Registration EudraCT 2021-003299-15 (https://www.clinicaltrialsregister.eu).

Schlagwörter

Stichwörter der Autor:innen

GDF-15HIVmetforminweight

Autor:innen und Institutionen

  • Department of Internal Medicine, HIV Unit, La Paz University Hospital, Madrid, Spain.
  • Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
  • CIBER of Infectious Diseases (CIBERINFEC), Madrid, Spain.
  • Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Department of Geriatrics, La Paz University Hospital, Madrid, Spain.
  • Department of Endocrinology and Nutrition, La Paz University Hospital, Madrid, Spain.

ORCID-Profile: Cristina Marcelo-Calvo, Rocío Montejano, Alejandro Díez-Vidal, José R Arribas

Förderung

  • Instituto de Salud Carlos III
  • European Union
  • Fondo Social Europeo

Zitieren

APA

Marcelo-Calvo, C., Esteban-Cantos, A., Jurado, F., Montejano, R., Gutiérrez-García, L., de Gea-Grela, A., Martínez-Martín, P., Díez-Vidal, A., de Miguel Buckley, R., Oñoro-López, C. M., González, J. C., Martín-Carbonero, L., Bernardino, J. I., Colino, R. M., de Villar, N. G. P., Rodés, B., & Arribas, J. R. (2026). Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial. Open Forum Infectious Diseases, 13(8). https://doi.org/10.1093/ofid/ofag489

Vancouver

Marcelo-Calvo C, Esteban-Cantos A, Jurado F, Montejano R, Gutiérrez-García L, de Gea-Grela A, et al. Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial. Open Forum Infectious Diseases. 2026;13(8). doi:10.1093/ofid/ofag489

BibTeX
@article{MarceloCalvo2026,
  author = {Marcelo-Calvo, Cristina and Esteban-Cantos, Andrés and Jurado, Francisco and Montejano, Rocío and Gutiérrez-García, Lucía and de Gea-Grela, Alejandro and Martínez-Martín, Patricia and Díez-Vidal, Alejandro and de Miguel Buckley, Rosa and Oñoro-López, Carlos M and González, Juan C and Martín-Carbonero, Luz and Bernardino, José I and Colino, Rocío Menéndez and de Villar, Noemí González Pérez and Rodés, Berta and Arribas, José R},
  title = {Metformin and Weight Changes in Non-diabetic Older People With HIV (METFORAGING): A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {8},
  doi = {10.1093/ofid/ofag489}
}
Kostenlos starten →